GlassScriptPhysician profile
Betty Aburime
NPI 1326467705
$2,927.25
in general payments reported to CMS, 2019-2025
30 companies · $876 in 2025
The $876 reported for 2025 was more than what 85% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $222 · 2022: $474 · 2023: $984 · 2024: $371 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,129 · Consulting Fee: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,129.41 |
| Consulting Fee | $101.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $811.33 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Csl Behring | $357.47 | 2022-2025 | Hizentra, Andembry, Haegarda |
| Genzyme Corporation | $266.55 | 2023 | |
| Glaxosmithkline, LLC. | $191.06 | 2022-2024 | Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $166.41 | 2021-2025 | Hyqvia, Takhzyro |
| Teva Pharmaceuticals USA, INC. | $129.40 | 2021-2022 | |
| Adma Biomanufacturing LLC | $124.09 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $91.83 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $88.90 | 2021-2023 | Dupixent |
| Abbvie INC. | $73.90 | 2025 | |
| Biocryst US Sales Co., LLC | $71.87 | 2022-2024 | Orladeyo |
| Pharming Healthcare, INC. | $68.07 | 2023-2025 | Ruconest |
| Abbott Laboratories | $66.10 | 2025 | Freestyle Libre 3 |
| Optinose US, INC. | $53.69 | 2022 | |
| Pfizer INC. | $49.37 | 2021-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $34.13 | 2025 | Edarbyclor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.84 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $26.09 | 2025 | Spravato |
| Axsome Therapeutics, INC. | $24.62 | 2025 | Auvelity |
| Alk-Abello, INC | $20.95 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $20.13 | 2025 | Rexulti |
| Noven Therapeutics, LLC | $19.96 | 2025 | Secuado, Xelstrym |
| Phathom Pharmaceuticals, INC. | $19.31 | 2025 | Voquezna |
| Lilly USA, LLC | $18.35 | 2025 | Jardiance |
| Novo Nordisk INC | $17.72 | 2025 | Wegovy |
| Tersera Therapeutics LLC | $17.63 | 2025 | Quzyttir |
| Bayer Healthcare Pharmaceuticals INC. | $17.10 | 2025 | |
| Paratek Pharmaceuticals, INC. | $16.64 | 2025 | Nuzyra, Xhance |
| Acella Pharmaceuticals, LLC | $15.78 | 2025 | NP Thyroid 60 |
| Exact Sciences Corporation | $14.96 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Betty Aburime listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.